-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Reinstates Buy on Insmed, Announces $188 Price Target

Benzinga·09/24/2026 13:44:02
Diffusion vocale
Goldman Sachs analyst Andrea Newkirk reinstates Insmed (NASDAQ:INSM) with a Buy and announces $188 price target.